GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » Debt-to-Equity

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Debt-to-Equity : 0.69 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Debt-to-Equity?

Biocytogen Pharmaceuticals (Beijing) Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$222.3 Mil. Biocytogen Pharmaceuticals (Beijing) Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$372.9 Mil. Biocytogen Pharmaceuticals (Beijing) Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$859.6 Mil. Biocytogen Pharmaceuticals (Beijing) Co's debt to equity for the quarter that ended in Dec. 2023 was 0.69.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Biocytogen Pharmaceuticals (Beijing) Co's Debt-to-Equity or its related term are showing as below:

HKSE:02315' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06   Med: 0.22   Max: 0.69
Current: 0.69

During the past 4 years, the highest Debt-to-Equity Ratio of Biocytogen Pharmaceuticals (Beijing) Co was 0.69. The lowest was 0.06. And the median was 0.22.

HKSE:02315's Debt-to-Equity is ranked worse than
80.62% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs HKSE:02315: 0.69

Biocytogen Pharmaceuticals (Beijing) Co Debt-to-Equity Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Debt-to-Equity Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
0.06 0.07 0.36 0.69

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Equity Get a 7-Day Free Trial 0.07 0.15 0.36 0.49 0.69

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's Debt-to-Equity

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocytogen Pharmaceuticals (Beijing) Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's Debt-to-Equity falls into.


Biocytogen Pharmaceuticals (Beijing) Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biocytogen Pharmaceuticals (Beijing) Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(222.255 + 372.88) / 859.586
=0.69

Biocytogen Pharmaceuticals (Beijing) Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(222.255 + 372.88) / 859.586
=0.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocytogen Pharmaceuticals (Beijing) Co  (HKSE:02315) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Biocytogen Pharmaceuticals (Beijing) Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » Debt-to-Equity
Comparable Companies
HKSE:06955 HKSE:02105 HKSE:06855 HKSE:02696 HKSE:02480 HKSE:00775 HKSE:01952 HKSE:02157 HKSE:02171 HKSE:02487 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
I54:Germany
Address
12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Website
https://www.biocytogen.com.cn
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC) and other solid tumors.
Executives
Bvcf Realization Fund, L.p. 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si 2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Yang Zhi 2201 Interest of corporation controlled by you
Innoveda Medtech, Ltd. 2201 Interest of corporation controlled by you
Ni Jian
Bvcf Realization Fund Gp, Ltd. 2201 Interest of corporation controlled by you
Bioveda China Fund Ii Rmb, Limited 2101 Beneficial owner
Cmbi Private Equity Series Spc 2201 Interest of corporation controlled by you
Cmb International Private Investment Limited 2201 Interest of corporation controlled by you
Cmb International Investment Management Limited 2201 Interest of corporation controlled by you

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Headlines

No Headlines